Fig. 4
From: Cas13b-mediated RNA targeted therapy alleviates genetic dilated cardiomyopathy in mice
hTNNT2R141W knockdown by PspCas13b significantly increases myofilament sensitivity to Ca2+. (A) Size of cardiomyocytes in WT, R141W and AAV9-PspCas13b-treated R141W (R141W + PspCas13b) mice. (B) Sarcomere length of cardiomyocytes in WT, R141W and R141W + PspCas13b mice. (C) Mean trajectory of normalized sarcomere length vs. fluorescence (F340/380) recorded in WT (n = 28), R141W (n = 21) and R141W + PspCas13b mouse myocytes (n = 26) stimulated at 1 Hz. (D) Measurements of T50 (E) Tau, and (F) peak height; n = 23 to 29 cells per group from 3 mice. Sarcomere and Ca2+ transients were recorded at a 1 Hz pacing stimulation frequency with MyoPacer Field Stimulator (IonOptix MA, USA). The error bars represent the SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA. T50, time to 50% decay